Welcome to our dedicated page for Biocryst Pharmaceuticals SEC filings (Ticker: BCRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) files a range of documents with the U.S. Securities and Exchange Commission that shed light on its operations as a biotechnology company focused on hereditary angioedema (HAE) and other rare diseases. On this page, you can review BioCryst’s SEC filings alongside AI-generated summaries that help explain complex disclosures in clear language.
Current Reports on Form 8-K are especially important for tracking material events at BioCryst. Recent 8-K filings describe key regulatory milestones, such as U.S. Food and Drug Administration approval of the New Drug Application for an oral pellet formulation of once-daily ORLADEYO® (berotralstat) for prophylactic therapy in pediatric HAE patients aged 2 to <12 years. Other 8-Ks cover quarterly financial results, preliminary revenue updates, and guidance for ORLADEYO net revenue, total revenue including RAPIVAB® (peramivir injection), and non-GAAP operating expenses.
Filings also document strategic transactions that shape BioCryst’s business model. One set of 8-Ks details the Stock Purchase Agreement and subsequent closing of the sale of BioCryst Ireland Limited, which held certain assets and rights related to the European ORLADEYO business, along with associated IP license, supply, brand support, transition services, and trademark license agreements. Another 8-K outlines the Agreement and Plan of Merger under which a BioCryst subsidiary will merge with Astria Therapeutics, Inc., including the cash-and-stock merger consideration, closing conditions, and potential delisting of Astria’s stock.
Governance and compensation developments also appear in BioCryst’s filings. Recent 8-Ks describe the planned retirement of the company’s President and Chief Executive Officer, the appointment of a new President and future CEO, the hiring of a new Chief Financial Officer, and related employment and separation agreements. Additional filings report inducement equity grants to new employees in accordance with Nasdaq Listing Rule 5635(c)(4).
Alongside these 8-Ks, investors can use this page to access BioCryst’s periodic reports on Forms 10-K and 10-Q (when available), which provide detailed discussions of risk factors, business strategy, and financial statements. Stock Titan’s AI tools highlight key sections of lengthy documents such as annual reports (10-K), quarterly reports (10-Q), and insider transaction filings (Form 4), helping you quickly understand revenue drivers, major agreements, executive changes, and other disclosures that may affect BCRX.
Frank Steven reported acquisition or exercise transactions in this Form 4 filing.
BIOCRYST PHARMACEUTICALS INC director Steven Frank received an equity grant of 1,285 shares of Common Stock on February 27, 2026. The shares were issued in lieu of 100% of his quarterly cash board member retainer of $11,250, reflecting a stock-based compensation choice rather than a market purchase. Following this award, he directly owns 18,903 shares of the company’s common stock.
McKee Amy E reported acquisition or exercise transactions in this Form 4 filing.
BIOCRYST PHARMACEUTICALS INC director Amy E. McKee reported receiving an award of 642 shares of common stock on February 27, 2026. The shares were issued in lieu of 50% of a quarterly cash board retainer of $11,250, bringing her direct holdings to 42,432 shares.
BioCryst Pharmaceuticals outlines a rare-disease focused strategy centered on hereditary angioedema (HAE) and other orphan conditions. The company’s core product, ORLADEYO, is an oral, once-daily prophylactic for HAE, now approved in multiple markets and expanded to children aged 2 to <12 years via a pellet formulation in the United States.
BioCryst is leveraging this commercial platform with a pipeline that includes navenibart, a Phase 3 anti‑kallikrein antibody for HAE acquired through the Astria Therapeutics merger, BCX17725 for Netherton syndrome, and avoralstat for diabetic macular edema. The report details extensive global partnerships for ORLADEYO, legacy influenza antiviral peramivir (RAPIVAB) supply to the U.S. Strategic National Stockpile, and a broad patent estate protecting kallikrein, antiviral, and other programs, while emphasizing numerous clinical, regulatory, competitive, financing, and operational risks that could impact profitability and growth.
BioCryst Pharmaceuticals reported a major turnaround in 2025, driven by its hereditary angioedema drug ORLADEYO. Total revenues reached $874.8 million, up from $450.7 million, and operating results swung from a small loss to $341.0 million of operating profit.
ORLADEYO net revenue was $601.8 million, up 38% year over year, or 43% excluding the divested European business. On a non-GAAP basis, total revenue was $592.9 million and operating profit $214.2 million, both sharply higher. Net income was $263.9 million, or $1.21 per diluted share, marking the company’s first full-year profitability.
Strategically, BioCryst sold its European ORLADEYO business, received FDA approval for an ORLADEYO oral pellet formulation for children with HAE, and completed the acquisition of Astria Therapeutics, adding Phase 3 antibody navenibart to its HAE portfolio. For 2026, it reaffirmed ORLADEYO revenue guidance of $625–$645 million and total revenue of $635–$660 million, with non-GAAP operating expenses expected between $450–$470 million.
BioCryst Pharmaceuticals, Inc. received an updated ownership report showing that Deerfield-related investment entities and James E. Flynn together beneficially own 14,341,000 shares of its common stock, representing 6.81% of the company as of 12/31/2025.
The shares are held through Deerfield Partners, L.P., with Deerfield Mgmt, L.P., Deerfield Management Company, L.P. and Flynn reporting shared power to vote and dispose of these shares, and no sole voting or dispositive power. The filers certify the holdings are not for the purpose of changing or influencing control of BioCryst.
State Street Corporation has filed a Schedule 13G reporting beneficial ownership of 11,073,211 shares of BioCryst Pharmaceuticals Inc. common stock, representing 5.3% of the class as of the event date.
State Street reports no sole voting or dispositive power, with shared voting power over 10,457,690 shares and shared dispositive power over 11,073,211 shares. The holdings are certified as acquired and held in the ordinary course of business, not to change or influence control of BioCryst. Several State Street Global Advisors entities are identified as relevant investment adviser subsidiaries.
BioCryst Pharmaceuticals director Jill C. Milne reported new equity holdings following a merger and standard director compensation grants. On 01/23/2026 she received 2,582 shares of BioCryst common stock in exchange for 4,377 Astria Therapeutics shares under a merger where each Astria share was converted into 0.59 BioCryst share plus $8.55 in cash.
She also acquired 12,272 restricted stock units as an automatic non-employee director grant that will vest in three equal annual installments starting one year after grant. In addition, she received an automatic stock option grant for 26,684 shares at an exercise price of $6.79, vesting 1/36 per month over three years and expiring on 01/23/2036.
BioCryst Pharmaceuticals director files initial ownership report showing no holdings
BioCryst Pharmaceuticals Inc. director Jill C. Milne filed an initial ownership report on Form 3 for the company’s common stock. The filing states that no non-derivative or derivative securities are beneficially owned, meaning she reports no current ownership position in BioCryst shares or related equity instruments.
BioCryst Pharmaceuticals, Inc. completed its previously agreed merger with Astria Therapeutics, Inc. on January 23, 2026. Axel Merger Sub, Inc., a wholly owned subsidiary of BioCryst, merged with and into Astria, and Astria now operates as a wholly owned subsidiary of BioCryst.
The filing also confirms that the appointment of Jill C. Milne, Ph.D. to BioCryst’s board of directors became effective on the merger closing date after conditions in the merger agreement were satisfied. On January 20, 2026, the board further appointed Dr. Milne to the Compensation Committee and the Science Committee, effective as of the closing date.